Business Context and Reporting Period
Company: Henry Schein, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 29, 2024 (Second Quarter of Fiscal 2024)
Business Overview: Henry Schein is a global provider of health care products and services to office-based dental and medical practitioners. Operations are conducted through two reportable segments: Health Care Distribution and Technology and Value-Added Services.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | Q2 2023 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|---|
| Net Sales | $3,136 million | $3,100 million | $6,308 million | $6,160 million |
| Gross Profit | $1,018 million | $975 million | $2,030 million | $1,941 million |
| Gross Margin | 32.5% | 31.4% | 32.2% | 31.5% |
| Operating Income | $159 million | $201 million | $309 million | $376 million |
| Net Income (Total) | $105 million | $148 million | $203 million | $276 million |
| Net Income (Attributable to HSIC) | $104 million | $140 million | $197 million | $261 million |
| Diluted EPS | $0.80 | $1.06 | $1.52 | $1.97 |
| Operating Cash Flow (YTD) | $493 million (vs. $301 million YTD 2023) | |||
| Total Debt | $2,502 million (as of June 29, 2024) | |||
| Cash & Equivalents | $138 million (as of June 29, 2024) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 1.1% in Q2 and 2.4% YTD compared to the prior year. Growth was driven by the Technology and Value-Added Services segment (+10.8% Q2, +12.3% YTD) and Medical distribution (+5.0% Q2, +6.2% YTD), partially offset by a decline in Dental distribution (-1.7% Q2, -0.5% YTD).
- Profitability Decline: Operating income decreased 21% in Q2 and 18% YTD. This was primarily due to increased operating expenses, including higher payroll costs, litigation settlements, and acquisition-related amortization.
- Cyber Incident Impact: The October 2023 cyber incident continued to impact results, causing a slower-than-anticipated recovery in sales to episodic customers. The company incurred $3 million in Q2 and $8 million YTD in direct expenses, partially offset by $10 million in insurance proceeds received YTD.
- Restructuring Costs: Restructuring costs decreased to $15 million in Q2 (vs. $18 million prior year) and $25 million YTD (vs. $48 million prior year) as the 2022 Plan neared completion.
- Acquisitions: Significant acquisitions included TriMed Inc. (60% interest, April 2024) and the completion of accounting for Shield Healthcare and S.I.N. Implant System.
Guidance, Outlook, and Risks
- Restructuring Plans: The 2022 restructuring plan was completed as of July 31, 2024, with an expected $12 million in remaining charges for the year. A new "2024 Plan" was announced on August 6, 2024, to integrate acquisitions and right-size operations; specific charge amounts are not yet determined.
- Share Repurchases: The Board authorized an additional $500 million share repurchase program on July 31, 2024. As of June 29, 2024, $90 million remained available under the prior authorization.
- Legal Proceedings:
- Cyber Incident Litigation: A class action settlement term sheet was agreed upon for the Cruz-Bermudez Action; the company expects the settlement amount to be immaterial.
- Opioid Litigation: The company is a defendant in multiple opioid-related lawsuits, though opioids represent less than 0.4% of net sales.
- False Claims Act: Claims against Henry Schein in a qui tam lawsuit regarding "Buy American" laws were dismissed without prejudice in July 2024.
- Tax Outlook: The effective tax rate increased to 25.2% YTD (vs. 22.8% prior year) due to state and foreign taxes. The company is monitoring the impact of OECD Pillar Two global minimum tax rules.
Investor Verification Checklist
- Cyber Incident Recovery: Verify the pace of sales recovery from episodic customers and the finality of insurance recoveries related to the October 2023 incident.
- 2024 Restructuring Plan: Monitor future filings for specific cost estimates and timing of charges related to the new 2024 restructuring plan announced in August.
- Acquisition Integration: Assess the financial impact and integration progress of recent acquisitions, specifically TriMed Inc., Shield Healthcare, and S.I.N. Implant System.
- Working Capital Trends: Review accounts receivable days sales outstanding (increased to 48.9 days) and inventory turns (increased to 5.0) to ensure liquidity remains stable despite cyber-related payment delays.
- Legal Exposure: Track the status of the opioid litigation and the final approval of the cyber incident class action settlement.